Lymphoma, B-CellClarity-BRNCT07882576
A Study to Evaluate Treatment Patterns and Investigate Adult Patients With B-cell Lymphoma
An observational study of Lymphoma, B-Cell, run by AstraZeneca at 5 sites in Brazil.
Trial summary
This is a retrospective observational registry study designed to characterise patient profiles, assess treatment patterns, evaluate clinical outcomes and explore COO testing patterns among adult patients with newly diagnosed LDGCB who have not previously received treatment (TN) and are receiving first-line (1L)… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lymphoma, B-Cell
- How many people
- 532 participants
- Where
- 5 sitesBrazil
- Study dates
- 30 Nov 2026to 30 Jan 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population consists of adult patients with a recent diagnosis of LDGCB who have not previously received treatment (TN) and who commenced systemic 1L therapy during the study identification period (1 January 2020 to 1 July 2024) in Brazil, Canada, France and the United Kingdom. Patients will be followed up until death, loss to follow-up or the end of the study period, whichever occurs first. Loss to follow-up will be defined individually for each dataset, but may include (i) the last interaction recorded in the data, (ii) the end of the continuous recruitment period, or (iii) another definition specific to each dataset.
Who may be able to join
- Patients with newly diagnosed LDGCB prior to the index date during the study identification period (1 January 2020 to 1 July 2024) in registries/databases in Brazil, Canada, France and the United Kingdom.
- Patients aged ≥ 18 years at the time of their first diagnosis of LDGCB.
- Patients who started eligible first-line systemic therapy during the study identification period (1 January 2020 to 1 July 2024).
- Identify patients who started palliative care during the study identification period (1 January 2020 to 31 December 2024).
Who cannot join
- Patients who were treated for another primary cancer diagnosis documented less than 5 years prior to the index event.
- Patients who received systemic treatment for LDGCB prior to the index event.
- Patients who received palliative care as first-line treatment.
- Patients who participated in a clinical trial after the index date (i.e. who received treatment for LDGCB as part of a clinical trial)
Trial locations and contacts
5 sites in 1 country. Contact the study team or a site near you to ask about taking part.
AstraZeneca Clinical Study Information Center contact
5 sites in 1 country
Brazil5 sites
UNICAMP
Campinas, São Paulo
Guilherme Duffles
Hospital Erasto Gaertner
Curitiba, Paraná
João Samuel Farias
AC Camargo Cancer Center
São Paulo
Talita Silveira
Hospital Israelita Albert Einstein
São Paulo
Guilherme Perini
Hospital Municipal da Vila Santa Catarina
São Paulo
Larissa Teixeira
About this study
Official title: WW-CLARITY: Real-world Characteristics, Treatments, and Outcomes of Treatment-Naïve (TN) Patients With Diffuse Large B- Cell Lymphoma (DLBCL) in the UK, France, Canada, and Brazil
This is a retrospective observational registry study designed to characterise patient profiles, assess treatment patterns, evaluate clinical outcomes and explore COO testing patterns among adult patients with newly diagnosed LDGCB who have not previously received treatment (TN) and are receiving first-line (1L) treatment.
Read the detailed description
This is a retrospective observational registry study designed to characterise patient profiles, assess treatment patterns, evaluate clinical outcomes and explore COO testing patterns among adult patients with newly diagnosed LDGCB who have not previously received treatment (TN) and are receiving first-line (1L) treatment. Patients who commenced first-line systemic treatment during the study identification period, from 1 January 2020 to one year prior to the end of the study period (which will vary according to the data source), will be eligible for inclusion in the study. Data will be collected, analysed and summarised separately for each participating country.
In Brazil, the study will use data available from the Study's Local Database - Einstein Hospital Israelita, including patient demographic data such as age and gender; clinical information such as diagnosis, disease stage, details of the patient's general condition and laboratory test results; and information on treatment.
- Conditions
- Lymphoma, B-Cell
- Keywords
- Lymphoma, B-Cell, High-grade B-cell lymphoma, RWE, Observational
- Medical subject headings
- Lymphoma, B-Cell, Lymphoma
What is being measured
The primary outcome is the main question the study is designed to answer.
Real-world progression-free survival (rwPFS), measured from the start of first-line (1L) treatment until clinically documented disease progression or death, with censoring at the time of the last contact.
Probability of survival at 2 years derived from the Kaplan-Meier analysis of real-world rwPFS (2- year rwPFS)
Measured: through study completation, an avarege 1 year
Secondary outcomes (5)
Distribution of first-line (1L) treatment regimens
It will be summarized using descriptive statistics and Kaplan-Meier methods.
Measured: through study completation, an avarege 1 year
Safety outcomes include hematologic and non-hematologic adverse events.
Safety will be assessed using adverse events that occurred during first-line treatment, with 95% confidence intervals.
Measured: through study completation, an avarege 1 year
Distribution of treatment patterns
It will be summarized using descriptive statistics and Kaplan-Meier methods
Measured: through study completation, an avarege 1 year
Distribution of overall survival
It will be summarized using descriptive statistics and Kaplan-Meier methods
Measured: through study completation, an avarege 1 year
Treatment time to next treatment or death
It will be summarized using descriptive statistics and Kaplan-Meier methods
Measured: through study completation, an avarege 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Oct 2026
- Study start30 Nov 2026 (estimated)
- Primary completion30 Jan 2027 (estimated)
- Study completion30 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lymphoma, B-CellStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 532 participants (estimated)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07882576
- Sponsor's protocol ID
- D8227R00003
- Acronym
- Clarity-BR
- Status last verified
- Oct 2026
- First submitted
- 28 Sep 2026
- Last updated
- 20 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- WW-CLARITY: Real-world Characteristics, Treatments, and Outcomes of Treatment-Naïve (TN) Patients With Diffuse Large B- Cell Lymphoma (DLBCL) in the UK, France, Canada, and Brazil
- ClinicalTrials.gov ID
- NCT07882576
- Acronym / sponsor ID
- Clarity-BR / D8227R00003
- Conditions
- Lymphoma, B-Cell
- Keywords
- Lymphoma, B-Cell, High-grade B-cell lymphoma, RWE, Observational
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 532 participants (estimated)
- Lead sponsor
- AstraZenecaIndustry (pharma, biotech, devices)
- Study start
- 30 Nov 2026 (estimated)
- Primary completion
- 30 Jan 2027 (estimated)
- Study completion
- 30 Jan 2027 (estimated)
- First posted
- 20 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a retrospective observational registry study designed to characterise patient profiles, assess treatment patterns, evaluate clinical outcomes and explore COO testing patterns among adult patients with newly diagnosed LDGCB who have not previously received treatment (TN) and are receiving first-line (1L) treatment.
Detailed description
This is a retrospective observational registry study designed to characterise patient profiles, assess treatment patterns, evaluate clinical outcomes and explore COO testing patterns among adult patients with newly diagnosed LDGCB who have not previously received treatment (TN) and are receiving first-line (1L) treatment. Patients who commenced first-line systemic treatment during the study identification period, from 1 January 2020 to one year prior to the end of the study period (which will vary according to the data source), will be eligible for inclusion in the study. Data will be collected, analysed and summarised separately for each participating country.
In Brazil, the study will use data available from the Study's Local Database - Einstein Hospital Israelita, including patient demographic data such as age and gender; clinical information such as diagnosis, disease stage, details of the patient's general condition and laboratory test results; and information on treatment.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population consists of adult patients with a recent diagnosis of LDGCB who have not previously received treatment (TN) and who commenced systemic 1L therapy during the study identification period (1 January 2020 to 1 July 2024) in Brazil, Canada, France and the United Kingdom. Patients will be followed up until death, loss to follow-up or the end of the study period, whichever occurs first. Loss to follow-up will be defined individually for each dataset, but may include (i) the last interaction recorded in the data, (ii) the end of the continuous recruitment period, or (iii) another definition specific to each dataset.
Key inclusion criteria (4 listed)
- Patients with newly diagnosed LDGCB prior to the index date during the study identification period (1 January 2020 to 1 July 2024) in registries/databases in Brazil, Canada, France and the United Kingdom.
- Patients aged ≥ 18 years at the time of their first diagnosis of LDGCB.
- Patients who started eligible first-line systemic therapy during the study identification period (1 January 2020 to 1 July 2024).
- Identify patients who started palliative care during the study identification period (1 January 2020 to 31 December 2024).
Key exclusion criteria (4 listed)
- Patients who were treated for another primary cancer diagnosis documented less than 5 years prior to the index event.
- Patients who received systemic treatment for LDGCB prior to the index event.
- Patients who received palliative care as first-line treatment.
- Patients who participated in a clinical trial after the index date (i.e. who received treatment for LDGCB as part of a clinical trial)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Real-world progression-free survival (rwPFS), measured from the start of first-line (1L) treatment until clinically documented disease progression or death, with censoring at the time of the last contact.
Time frame: through study completation, an avarege 1 year
Probability of survival at 2 years derived from the Kaplan-Meier analysis of real-world rwPFS (2- year rwPFS)
5 secondary outcomes
Distribution of first-line (1L) treatment regimens
Time frame: through study completation, an avarege 1 year
Safety outcomes include hematologic and non-hematologic adverse events.
Time frame: through study completation, an avarege 1 year
Distribution of treatment patterns
Time frame: through study completation, an avarege 1 year
Distribution of overall survival
Time frame: through study completation, an avarege 1 year
Treatment time to next treatment or death
Time frame: through study completation, an avarege 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2026.
- Individual participant dataSharing planned: Yes. Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Related trials for Lymphoma, B-Cell
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Study of Oral MRT-2359 in Selected Cancer Patients
NSCLC, SCLC
Recruiting
A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...
B-All, Acute Lymphoblastic Leukemia
Active, not recruitingPhase 2
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
B Cell ALL, B-Cell Lymphoma
Active, not recruitingEarly Phase 1
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
B-ALL, DLBCL
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
AstraZeneca Clinical Study Information Center contact
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lymphoma, B-Cell, run by AstraZeneca at 5 sites in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 20 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact AstraZeneca Clinical Study Information Center (1-877-240-9479, information.center@astrazeneca.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Real-world progression-free survival (rwPFS), measured from the start of first-line (1L) treatment until clinically documented disease progression or death, with censoring at the time of the last contact. (time frame: through study completation, an avarege 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2026; AzTrials last refreshed its copy on 7 Nov 2026.